[Pilot study of the effect of interferon-alpha on atopic eczema].
In this pilot study 12 patients with moderate to severe atopic eczema were treated with 2 million IU interferon alpha 2a (Roferon A) three times weekly for 8 weeks and followed up for a further 10 weeks: 2 patients showed clear and 9 a slight to moderate reduction of their skin lesions; 1 patient got worse. Pruritus did not decrease and even increased in a few patients, and IgE levels showed no change during and after treatment. All patients noted mild, transient, flu-like symptoms. The efficacy of interferon alpha in the present therapeutic design for the treatment of atopic eczema must thus be classified as only moderate.
Kropp
J D
JD
Hautklinik und Hautpolinklinik, Universitätsklinikum Rudolf Virchow, Freie Universität Berlin.
Algermissen
B
B
Buck
S
S
Czarnetzki
B M
BM
D000328:Adult; D003876:Dermatitis, Atopic / Q000276:immunology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007073:Immunoglobulin E
Pilotstudie zur Wirkung von Interferon alpha beim atopischen Ekzem.